Business
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
WALTHAM, Mass.--(BUSINESS WIRE)-- La Jolla Pharmaceutical Company, a wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) dedicated to the
About this update from Innoviva, Inc.
[{"type":"text","content":" WALTHAM, Mass.--(BUSINESS WIRE)--\nLa Jolla Pharmaceutical Company, a wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that five abstracts highlighting XERAVA (eravacycline) have been selected for poster presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.\n\nDetails of the presentations are as follows:\n\nTitle: Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection\nPresenter: Austin Morrison, PharmD\nAbstract #: 390\nDate and time: Thursday, October 20, 2022, 12:15pm – 1:30pm ET\nLocation: Hall B + C\n\nTitle: Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints\nPresenter: Ashlan Kunz Coyne, PharmD\nAbstract #: 633\nDate and time: Thursday, October 20, 2022, 12:15pm – 1:30pm ET\nLocation: Hall B + C\n\nTitle: Combination Eravacycline Therapy for Carbapenem-Resistant Acinetobacter baumannii Pneumonia\nPresenter: Melissa Jackson, PharmD\nAbstract #: 655\nDate and time: Thursday, October 20, 2022, 12:15pm – 1:30pm ET\nLocation: Hall B + C\n\nTitle: Residual Infusion Performance Evaluation (RIPE): A Single-Center Evaluation of Residual Volume Post-Intravenous Eravacycline Infusion\nPresenter: Alysa Baumann, PharmD, MBA\nAbstract #: 1017\nDate and time: Friday, October 21, 2022, 12:15pm – 1:30pm ET\nLocation: Hall B + C\n\nTitle: Susceptibility of Gram-Negative Clinical Isolates Collected from the USA in 2020 to Eravacycline and Comparators\nPresenter: Stephen Hawser, PhD\nAbstract #: 1679\nDate and time: Friday, Saturday 22, 2022, 12:15pm – 1:30pm ET\nLocation: Virtual\n\nAbout XERAVA\n\nXERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA is approved by the European Commission (EC) for the treatment of cIAI in adults. Prescribing information for XERAVA is available at www.xerava.com. and www.ema.europa.eu/en/medicines/human/EPAR/xerava. XERAVA is marketed in the U.S. by Tetraphase ...